Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WD-890 in moderate to severe plaque psoriasis
NCT06912165Phase 2Recruiting
- Sponsor
- Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of WD-890 in plaque psoriasis (4 arms), sponsored by Zhejiang Wenda Pharmaceutical Technology Co., Ltd. Primary endpoint: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at 16 weeks. Started Dec 2024; status: recruiting.
02
Drugs
WD-890
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06912165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06912165.